Mild Cognitive Impairment

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Promise of microRNAs as Alzheimer’s disease markers

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

The regulatory role of nicotinic receptors in cognitive functioning

How effective are cholinergic agents beyond MCI?

Clinical implementations of AlzoSure Predict

Longitudinal clinical outcomes of tau-PET-positive individuals

Associations between predicted brain age and Alzheimer’s Disease biomarkers

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

The future of SAGE-718 in Alzheimer’s disease treatment

Biomarkers for early detection of Alzheimer’s disease: microRNAs

Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD

New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway

Long-term transdermal nicotine for the treatment of mild cognitive impairment

Phase II clinical trial of SAGE-718 for the treatment of MCI and early AD

EXERT: why was strength/balance training as effective as cardio in preventing cognitive decline?